Dr. Jeffrey Glenn is a Professor of Medicine, Microbiology & Immunology at Stanford University, and the Director of the Center for Hepatitis and Liver Tissue Engineering. He is the founder of Eiger Biopharmaceuticals who is developing Lambda for hepatitis delta and COVID.

Dr. Glenn is an author on over 100 scientific articles and book chapters, and has been an active consultant for a variety of biotechnology and large pharmaceutical companies. He is the principal investigator on multiple NIH grants, and a member of FDA Antiviral Drugs.

He is an international authority on developing novel antiviral therapeutics.

Director of Graduate Program, Department of Microbiology & Immunology, Stanford University School of Medicine (2002-Present)Member of the Committee on Graduate Studies, Stanford University (2001-2004)Member of School of Medicine Awards Committee, Stanford University School of Medicine (2005-Present)Chair, Dept. of Microbiology & Immunology, Stanford University School of Medicine (2010-2017)

Originally from Seoul, South Korea, Dr. Cho is a graduate of the University of California, Berkeley and Stanford University. Dr. Cho earned his doctorate in Chemical Engineering at Stanford under the guidance of Professor Curtis W. Frank. During his graduate studies, Dr. Cho first gained an interest in research at the interface of molecular virology and biomaterials. The principal goal of his thesis work was to develop lab-on-a-chip technologies for analysis of viral protein interactions with lipid membranes. Dr. Cho then continued his postdoctoral training in Professor Jeffrey S. Glenn's group in the Division of Gastroenterology and Hepatology at the Stanford University School of Medicine. He applied these engineering technologies to combat the hepatitis C virus (HCV), which affects over 170 million people worldwide. His work has led to significant advances for treating HCV, including new drugs currently in preclinical or clinical trials.

In addition, Dr. Cho has pioneered a novel approach to liver tissue engineering that has provided improved methods to study liver disease.In addition to his leadership of the Translational Science Group, Dr. Cho is active in the NTU community and serves as Deputy Director of the Nanyang Institute of Technology in Health and Medicine (NITHM) as well as Director of NTU's Research Experience for Undergraduates (REU) summer program in collaboration with the Asian Research Network. He is also a Principal Investigator at the Singapore- MIT Alliance for Research and Technology (SMART) and a Visiting Associate Professor at the Stanford University School of Medicine.

Dr. Cho's passion for translational and regenerative medicine has been recognized by several prestigious international honors and awards from the American Liver Foundation, Beckman Foundation, and leading global universities and companies including Chalmers University of Technology and Roche Ltd. In 2011, Dr. Cho was named an NRF Fellow by the Singapore National Research Foundation, and was also appointed to a Nanyang Associate Professorship. Dr. Cho is also the Founder of infollutionZERO, a global nonprofit organization committed to building a green digital world for future generations by raising awareness of infollution (information + pollution) in digital space and promoting digital literacy.

Priscilla earned her PhD in Bio-organic Chemistry at the University of California, Berkeley. Following postdoctoral training in viral immunology at Scripps Research, she started her independent career at Harvard Medical School, where her laboratory combined chemical and pharmacological approaches to address fundamental and translational problems in virology. She is currently Professor in the Department of Microbiology and Immunology and the Stanford University School of Medicine where she focuses on leading and mentoring a multidisciplinary group of scientists focused on discovery and validation of new antiviral targets; identifying new strategies to achieve broad-spectrum activity and to avoid antiviral resistance; and investigating the function of lipid membranes in RNA virus replication. She is a strong advocate for diversity, equity, and inclusion in science.

Our lab applies biochemical and engineering principles to the development of protein-based tools for imaging and control of biochemical processes. Topics of investigation include fluorescent proteins structure and biophysics, fluorescent protein-based biosensors, neuronal activity sensors, spatiotemporal analysis of protein translation pathways, chemical control of protein translation, and light-responsive proteins.

Professor and Chair of Microbiology and Immunology at University of North Carolina at Chapel Hill School of Medicine

He then joined the laboratory of Professor Jeffrey Glenn's at Stanford School of Medicine as a postdoctoral fellow in 2000 then became a senior research scientist. He initially focused his research on how RNA viruses harness cellular membrane to support their genome’s replication. In recent years, his research expanded to include broad spectrum antivirals targeting host function; viral genome RNA structures as antiviral targets; and other direct-targeting antivirals